ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2276

Signature of Circulating Micro-RNA in Systemic Lupus Erythematosus

Anting L. Carlsen1, Aaron J. Schetter2, Christoffer T. Nielsen3, Christian Lood4, Steen Knudsen5, Anne Voss6, Curtis C. Harris7, Thomas Hellmark8, Mårten Segelmark9, Søren Jacobsen10, Anders A. Bengtsson4 and Niels H. H. Heegaard11, 1Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 2National Cancer Institute, National Institutes of Health, Bethesda, MD, 3Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, 4Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 5Medical Prognosis Institute, Horsholm, Denmark, 6Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, 7Laboratory of Human Carcinogenesis, National Cancer Institute NIH, Bethesda, MD, 8Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 9Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, 10Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 11Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Diagnosis and systemic lupus erythematosus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by chronic inflammation sustained by a type I interferon response. The diagnostic value of circulating micro-RNA (miRNA) signatures in SLE has not been systematically evaluated and compared to healthy controls and other autoimmune conditions.

Methods: We quantified 45 mature miRNAs in 409 plasma samples from clinically well-characterized SLE patients, healthy controls, and controls with other systemic autoimmune diseases (RA and vasculitis) and immunosuppressed patients (kidney transplant recipients). SLE risk probability scores were modeled by logistic regression and validated in independent cohorts.

Results: Highly significant changes in 7 specific miRNAs were identified and validated independently. Up-regulated miRNAs were miR-142-3p and -181a and down-regulated miRNAs were miR-106a, -17, -20a, -92a, and -203. Four of five down-regulated miRNAs represent members of the polycistronic miR-17-92 family and, together with miR-223, were significantly lower in SLE patients with active nephritis than in patients without nephritis. A predictive model for the SLE diagnosis based on 2 miRNAs discriminated SLE from controls (AUC=0.89) when validated independently (accuracy: 76%, p<2x10-9). Using a 4 miRNA model SLE cases was grouped statistically significantly different from disease controls except for vasculitis samples.

Conclusion: We find consistent changes of circulating miRNA profiles in SLE patients compared with healthy controls and disease controls. All 7 validated differently expressed miRNAs target genes in the TGF-b signaling pathway. Other targets imply regulation of apoptosis, cytokine-cytokine receptors, T-cell development, and cytoskeletal organization. A four-miRNA signature was diagnostic for SLE, and patients with active nephritis showed specific subset miRNA profiles. The findings highlight possible deregulated pathways in SLE and suggest that circulating miRNA signatures may potentially be used diagnostically and for monitoring purposes in SLE.


Disclosure:

A. L. Carlsen,
None;

A. J. Schetter,
None;

C. T. Nielsen,
None;

C. Lood,
None;

S. Knudsen,
None;

A. Voss,
None;

C. C. Harris,
None;

T. Hellmark,
None;

M. Segelmark,
None;

S. Jacobsen,
None;

A. A. Bengtsson,
None;

N. H. H. Heegaard,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/signature-of-circulating-micro-rna-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology